Anti-PD-L1 antibodies and uses therefor
AssigneesEmory University, Dana-Farber Cancer Institute, Inc.
InventorsGordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
Life of this patent
Estimating the term…
Abstract
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
Claims12
An isolated antibody or antigen-binding fragment thereof, comprising:
- a) a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:
- 13-15;
- and/or
- b) a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:16-18,
- wherein the isolated antibody, or antigen-binding fragment thereof, binds to a PD-L1 protein having the amino acid sequence of SEQ ID NO:
- 4, and the isolated antibody, or antigen-binding fragment thereof, is chimeric, humanized, composite, or human.
A pharmaceutical composition, comprising an isolated antibody or antigen-binding fragment thereof and a pharmaceutically-acceptable carrier, wherein the antibody or antigen-binding fragment thereof comprises:
- a) a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:
- 13-15;
- and/or
- b) a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:16-18,
- wherein the isolated antibody, or antigen-binding fragment thereof, binds to a PD-L1 protein having the amino acid sequence of SEQ ID NO:
- 4, and the isolated antibody, or antigen-binding fragment thereof, is chimeric, humanized, composite, or human.
A method of producing an antibody or antigen-binding fragment thereof, comprising culturing a cell that produces the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment produced by the cell, wherein the antibody or antigen-binding fragment thereof comprises:
- a) a heavy chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:
- 13-15;
- and/or
- b) a light chain variable region sequence comprising the three CDRs with the sequences of SEQ ID NOs:16-18,
- wherein the antibody, or antigen-binding fragment thereof, binds to a PD-L1 protein having the amino acid sequence of SEQ ID NO:
- 4, and the antibody, or antigen-binding fragment thereof, is chimeric, humanized, composite, or human.
Dependencies are inferred from the claim text.